Development and validation of modified Liaoning score for predicting the prognosis of liver cirrhosis: a retrospective, international multicenter, observational study.

IF 3.8 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Expert Review of Gastroenterology & Hepatology Pub Date : 2024-01-01 Epub Date: 2024-02-27 DOI:10.1080/17474124.2024.2320238
Xiaoting Song, Fernando Gomes Romeiro, Jing Wang, Yue Yin, Cyriac Abby Philips, Xinyi Yang, Xiaofeng Liu, Wenming Wu, Marcos Vinícius Tiveli Bernardinelli, Roger Santos de Souza, Arif Hussain Theruvath, Su Lin, Xingshun Qi
{"title":"Development and validation of modified Liaoning score for predicting the prognosis of liver cirrhosis: a retrospective, international multicenter, observational study.","authors":"Xiaoting Song, Fernando Gomes Romeiro, Jing Wang, Yue Yin, Cyriac Abby Philips, Xinyi Yang, Xiaofeng Liu, Wenming Wu, Marcos Vinícius Tiveli Bernardinelli, Roger Santos de Souza, Arif Hussain Theruvath, Su Lin, Xingshun Qi","doi":"10.1080/17474124.2024.2320238","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Liaoning score has been developed and validated to predict the risk of esophageal varices in liver cirrhosis. This study aimed to further modify the Liaoning score by combining clinical and laboratory parameters to predict the long-term outcome of cirrhotic patients.</p><p><strong>Methods: </strong>First, 474 cirrhotic patients were retrospectively enrolled from Shenyang, China as the training cohort. Independent predictors for death were identified by competing risk analyses, and then a new prognostic model, called as modified Liaoning score, was developed. Its performance was externally validated at three centers from Fuzhou, China (<i>n</i> = 1944), Jinan, China (<i>n</i> = 485), and São Paulo, Brazil (<i>n</i> = 221).</p><p><strong>Results: </strong>Age, total bilirubin (TBIL), albumin (ALB), serum creatinine (SCr), and Liaoning score were independently associated with death in the training cohort. Modified Liaoning score = 0.159×Liaoning score + 0.010×TBIL(µmol/L)+0.029×age(years)+0.011×SCr(µmol/L)-0.037×ALB(g/L). The area under curve of modified Liaoning score was 0.714 (95%CI = 0.655-0.773), which was higher than that of Child-Pugh score (0.707, 95%CI = 0.645-0.770), MELD score (0.687, 95%CI = 0.623-0.751), and Liaoning score (0.583, 95%CI = 0.513-0.654). A modified Liaoning score of ≥ 1.296 suggested a higher cumulative incidence of death in liver cirrhosis (<i>p</i> < 0.001). Modified Liaoning score still had the highest prognostic performance in Chinese and Brazilian validation cohorts.</p><p><strong>Conclusions: </strong>Modified Liaoning score can be considered for predicting the long-term outcome of cirrhotic patients.</p>","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"121-128"},"PeriodicalIF":3.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474124.2024.2320238","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Liaoning score has been developed and validated to predict the risk of esophageal varices in liver cirrhosis. This study aimed to further modify the Liaoning score by combining clinical and laboratory parameters to predict the long-term outcome of cirrhotic patients.

Methods: First, 474 cirrhotic patients were retrospectively enrolled from Shenyang, China as the training cohort. Independent predictors for death were identified by competing risk analyses, and then a new prognostic model, called as modified Liaoning score, was developed. Its performance was externally validated at three centers from Fuzhou, China (n = 1944), Jinan, China (n = 485), and São Paulo, Brazil (n = 221).

Results: Age, total bilirubin (TBIL), albumin (ALB), serum creatinine (SCr), and Liaoning score were independently associated with death in the training cohort. Modified Liaoning score = 0.159×Liaoning score + 0.010×TBIL(µmol/L)+0.029×age(years)+0.011×SCr(µmol/L)-0.037×ALB(g/L). The area under curve of modified Liaoning score was 0.714 (95%CI = 0.655-0.773), which was higher than that of Child-Pugh score (0.707, 95%CI = 0.645-0.770), MELD score (0.687, 95%CI = 0.623-0.751), and Liaoning score (0.583, 95%CI = 0.513-0.654). A modified Liaoning score of ≥ 1.296 suggested a higher cumulative incidence of death in liver cirrhosis (p < 0.001). Modified Liaoning score still had the highest prognostic performance in Chinese and Brazilian validation cohorts.

Conclusions: Modified Liaoning score can be considered for predicting the long-term outcome of cirrhotic patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于预测肝硬化预后的改良辽宁评分的开发与验证:一项回顾性国际多中心观察研究。
背景:辽宁评分已被开发并验证用于预测肝硬化食管静脉曲张的风险。本研究旨在结合临床和实验室指标,进一步修改辽宁评分,以预测肝硬化患者的长期预后:方法:首先,从中国沈阳回顾性招募 474 名肝硬化患者作为训练队列。通过竞争风险分析确定了死亡的独立预测因素,然后建立了一个新的预后模型,称为 "改良辽宁评分"。该模型的性能在中国福州(n = 1944)、中国济南(n = 485)和巴西圣保罗(n = 221)的三个中心进行了外部验证:结果:在培训队列中,年龄、总胆红素(TBIL)、白蛋白(ALB)、血清肌酐(SCr)和辽宁评分与死亡独立相关。修正辽宁评分 = 0.159× 辽宁评分 + 0.010×TBIL(µmol/L)+0.029× 年龄(岁)+0.011×SCr(µmol/L)-0.037×ALB(g/L)。改良辽宁评分的AUC为0.714(95%CI = 0.655-0.773),高于Child-Pugh评分(0.707,95%CI = 0.645-0.770)、MELD评分(0.687,95%CI = 0.623-0.751)和辽宁评分(0.583,95%CI = 0.513-0.654)。改良辽宁评分≥1.296表明肝硬化患者的累积死亡发生率较高(p 结论:改良辽宁评分可被视为肝硬化患者死亡的重要依据:改良辽宁评分可用于预测肝硬化患者的长期预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Expert Review of Gastroenterology & Hepatology
Expert Review of Gastroenterology & Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
6.80
自引率
2.60%
发文量
86
审稿时长
6-12 weeks
期刊介绍: The enormous health and economic burden of gastrointestinal disease worldwide warrants a sharp focus on the etiology, epidemiology, prevention, diagnosis, treatment and development of new therapies. By the end of the last century we had seen enormous advances, both in technologies to visualize disease and in curative therapies in areas such as gastric ulcer, with the advent first of the H2-antagonists and then the proton pump inhibitors - clear examples of how advances in medicine can massively benefit the patient. Nevertheless, specialists face ongoing challenges from a wide array of diseases of diverse etiology.
期刊最新文献
Cellular senescence and its pathogenic and therapeutic implications in autoimmune hepatitis. Implications of the microbiome after pancreatic cancer resection with regards to morbidity & mortality. Diagnosing and managing gastroparesis - where are we now? Interrupting inflammatory bowel disease therapy: why, who, when and how to consider medication holidays. Therapeutic drug monitoring in inflammatory bowel disease: recent developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1